Vyera Pharmaceuticals

Last updated
Vyera Pharmaceuticals
Company type Private
Industry Pharmaceuticals
FoundedFebruary 2015;9 years ago (2015-02)
Founder
Headquarters New York City and Zug, Switzerland
Key people
Justin Garrett [1]
Chief Executive Officer
ProductsVecamyl, Daraprim
Website www.vyera.com

Vyera Pharmaceuticals (formerly Turing Pharmaceuticals) is a pharmaceutical company incorporated in Zug, Switzerland, with offices in New York City. The company started to do business in the US as Vyera Pharmaceuticals in September 2017. [2] [3]

Contents

The company has two marketed products: Daraprim (pyrimethamine), for the treatment of toxoplasmosis, and Vecamyl (mecamylamine hydrochloride) for the treatment of hypertension. The company was widely criticized for raising the price of daraprim by 5456% following its acquisition of rights to the drug in 2015. The company's stock price dropped around 10% after the price increase of the drug. [4] CEO Martin Shkreli faced immense criticism for his actions. [5] The company was previously named after Alan Turing, the computer scientist.

On May 10, 2023, Vyera filed for Chapter 11 bankruptcy. [6]

Background

Turing Pharmaceuticals was launched in February 2015 by Martin Shkreli with the acquisition of three major assets from an orphan drug developer called Retrophin: an intranasal formulation of ketamine, an oxytocin nasal solution, and Vecamyl. [7] The company acquired the US marketing rights to Daraprim from Impax Laboratories in August 2015. [8]

In September 2015, Turing raised the price of Daraprim from $13.50 to $750 a tablet. This increase prompted widespread criticism of the company from many quarters, including the pharmaceutical industry itself. [9]

Shkreli resigned as Turing Pharmaceuticals' CEO on 18 December 2015, following his arrest on charges of defrauding investors in his former hedge fund. [10]

Daraprim

Daraprim is the trade name for the drug pyrimethamine, which is indicated for the treatment of toxoplasmosis in combination with a sulfonamide, and has been available since 1953. [11] At the time of the Daraprim acquisition Turing Pharmaceuticals indicated that it intended to develop new toxoplasmosis drug candidates with better ADME than Daraprim.

In response to criticisms of the September 2015 price increases, Turing Pharmaceuticals announced various patient affordability and access initiatives [12] and in November 2015 the company reduced the cost of Daraprim for hospitals by up to 50% of the increased rate. [13] Despite these partial rollbacks to the initial price increase, according to February 2, 2016, memo from Representative Elijah Cummings to the United States House Committee on Oversight and Government Reform, since Turing's acquisition to the rights in Daraprim, the drug has gone from being affordable and readily available to being prohibitively expensive. [14]

In January 2020 the FTC filed a case against Vyera "alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim". [15] A settlement was reached in December 2021. According to AP News, the settlement "requires Vyera and Phoenixus to provide up to $40 million in relief over 10 years to consumers who allegedly were fleeced by their actions and requires them to make Daraprim available to any potential generic competitor at the cost of producing the drug." [16] According to Law360, Kevin Mulleady "agreed to a seven-year ban on working for or holding more than an 8% share in most pharmaceutical companies." [17]

Vecamyl

Vecamyl is currently indicated for the treatment of hypertension.

Pipeline

Syntocinon

This product, also called TUR-001, is Turing Pharmaceuticals' oxytocin nasal solution. Syntocinon, short for 'synthetic oxytocin', was first introduced by the Swiss pharmaceutical company Sandoz in 1956. The product had gained FDA approval in 1960 to assist in initial postpartum milk ejection, but was discontinued by Sandoz's successor company, Novartis, in 1997 because of poor sales. Retrophin had licensed the product from Novartis in December 2013 in order to bring it back to the market for postpartum milk ejection as well as look into its use in the treatment of schizophrenia and autism. [18] Turing Pharmaceuticals is preparing for a Phase III in lactation and other indications are planned.

TUR-002

This product is Turing Pharmaceuticals' intranasal formulation of racemic ketamine. The company is working on the product for the treatment of suicidality.

TUR-004

This product is under development for the treatment of seizures associated with severe epilepsy disorders. Turing Pharmaceuticals made an IND filing for TUR-004 in October 2015 [19] and the product was granted Fast Track designation by the FDA. A Phase I Clinical Trial of TUR 004 for epileptic encephalopathies commenced in November 2015. [20]

Other products in development

Turing Pharmaceuticals is also working on TRP-001 for glycogen storage disorders, TRP-002 for developmental disorder, TRP-003 for leukodystrophy, TRP-004 for toxoplasmosis, TRP-005 for epileptic encephalopathy, and TRP-011 for congenital metabolic disorder.

Related Research Articles

<span class="mw-page-title-main">Pharmaceutical Research and Manufacturers of America</span> Trade group

Pharmaceutical Research and Manufacturers of America, formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. PhRMA is headquartered in Washington, DC.

<span class="mw-page-title-main">Sydney Grammar School</span> Grammar school in Sydney, Australia

Sydney Grammar School is an independent, fee-paying, non-denominational day school for boys, located in Sydney, Australia.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

<span class="mw-page-title-main">Pyrimethamine</span> Medication

Pyrimethamine, sold under the brand name Daraprim among others, is a medication used with leucovorin to treat the parasitic diseases toxoplasmosis and cystoisosporiasis. It is also used with dapsone as a second-line option to prevent Pneumocystis jiroveci pneumonia in people with HIV/AIDS. It was previously used for malaria but is no longer recommended due to resistance. Pyrimethamine is taken by mouth.

Epilepsy in animals is a group of neurological disorders characterized by seizures, caused by uncontrolled, abnormal bursts of electrical activity in the brain. They can start and stop very abruptly and last any amount of time from a few seconds to a few minutes. Canine epilepsy is often genetic but epilepsy in cats and other pets is rarer, likely because there is no hereditary component to epilepsy in these animals.

<span class="mw-page-title-main">Mecamylamine</span> Antihypertensive drug

Mecamylamine is a non-selective, non-competitive antagonist of the nicotinic acetylcholine receptors (nAChRs) that was introduced in the 1950s as an antihypertensive drug. In the United States, it was voluntarily withdrawn from the market in 2009 but was brought to market in 2013 as Vecamyl and eventually was marketed by Turing Pharmaceuticals.

<span class="mw-page-title-main">Tiopronin</span> Chemical compound

Tiopronin, sold under the brand name Thiola, is a medication used to control the rate of cystine precipitation and excretion in the disease cystinuria.

Medication costs, also known as drug costs are a common health care cost for many people and health care systems. Prescription costs are the costs to the end consumer. Medication costs are influenced by multiple factors such as patents, stakeholder influence, and marketing expenses. A number of countries including Canada, parts of Europe, and Brazil use external reference pricing as a means to compare drug prices and to determine a base price for a particular medication. Other countries use pharmacoeconomics, which looks at the cost/benefit of a product in terms of quality of life, alternative treatments, and cost reduction or avoidance in other parts of the health care system. Structures like the UK's National Institute for Health and Clinical Excellence and to a lesser extent Canada's Common Drug Review evaluate products in this way.

<span class="mw-page-title-main">Nasal administration</span> Administration of drugs through the nose

Nasal administration, popularly known as snorting, is a route of administration in which drugs are insufflated through the nose. It can be a form of either topical administration or systemic administration, as the drugs thus locally delivered can go on to have either purely local or systemic effects ibuprofen or Tylenol for headaches along with pains such as severe toothaches. Nasal sprays are locally acting drugs such as decongestants for cold and allergy treatment, whose systemic effects are usually minimal. Examples of systemically active drugs available as nasal sprays are migraine drugs, rescue medications for overdose and seizure emergencies, hormone treatments, nicotine nasal spray, and nasal vaccines such as live attenuated influenza vaccine.

Sulfadoxine/pyrimethamine, sold under the brand name Fansidar, is a combination medication used to treat malaria. It contains sulfadoxine and pyrimethamine. For the treatment of malaria it is typically used along with other antimalarial medication such as artesunate. In areas of Africa with moderate to high rates of malaria, three doses are recommended during the second and third trimester of pregnancy.

<span class="mw-page-title-main">Martin Shkreli</span> American financial criminal and businessman (b. 1983)

Martin Shkreli is an American investor and businessman. He was convicted of financial crimes for which he served over six years in federal prison and was fined over 70 million dollars. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.

Specialty drugs or specialty pharmaceuticals are a recent designation of pharmaceuticals classified as high-cost, high complexity and/or high touch. Specialty drugs are often biologics—"drugs derived from living cells" that are injectable or infused. They are used to treat complex or rare chronic conditions such as cancer, rheumatoid arthritis, hemophilia, H.I.V. psoriasis, inflammatory bowel disease and hepatitis C. In 1990 there were 10 specialty drugs on the market, around five years later nearly 30, by 2008 200, and by 2015 300.

Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.

Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.

Access to medicines refers to the reasonable ability for people to get needed medicines required to achieve health. Such access is deemed to be part of the right to health as supported by international law since 1946.

<span class="mw-page-title-main">Four Thieves Vinegar Collective</span> Anarchist biohacking group

The Four Thieves Vinegar Collective is an anarchist biohacking group founded in 2015 by Michael Laufer. They have published instructions for the "EpiPencil", an epinephrine autoinjector, and the "Apothecary MicroLab", a do-it-yourself (DIY) device intended to make a variety of medications, most notably pyrimethamine (Daraprim). The medical community has criticized them for causing potential harm to patients with the DIY instructions, but Laufer claims to defend people's right to attempt their medical treatment.

The Pharmaceutical Accountability Foundation was established in Amsterdam in July 2018 to deal with pharmaceutical companies that demand excessive prices for medicines in the Netherlands. This followed a report by the Raad voor de Volksgezondheid en Zorg in 2017. Wilbert Bannenberg, an epidemiologist, is the chairman. The group plans to deploy both health and pharmaceutical expertise and lawyers.

<span class="mw-page-title-main">Alice Motion</span> British chemist and science communicator (born 1984)

Alice Elizabeth Motion is a British chemist, science communicator, and associate professor at the School of Chemistry, University of Sydney. She is the founder of the Breaking Good project which encourages high school and undergraduate students to take part in research that can benefit human health. In 2018, the Breaking Good project was a finalist on the Google.org Impact Challenge.

<span class="mw-page-title-main">Matthew Todd (chemist)</span> British chemist (born 1973)

Matthew Houghton Todd is a British chemist and the Professor and Chair of Drug Discovery of the School of Pharmacy at University College London. He is the founder of Open Source Malaria (OSM) and his research focuses on drug discovery and development for this disease. Recently, he has expanded to other areas, particularly neglected diseases such as tuberculosis and mycetoma in the Open Source Tuberculosis (OSTB) and Open Source Mycetoma (MycetOS) project, through a collaboration with the Drugs for Neglected Diseases Initiative and Erasmus MC. In addition, he has some research activity in catalysis and methodology.

References

  1. "Leadership Team". Turing Pharmaceuticals. Retrieved 20 December 2016.
  2. "Corporation Filings 08/27/2017 to 09/03/2017". Louisiana Secretary of State. Archived from the original on 15 January 2022. Retrieved 24 September 2017.
  3. "Oxytocin intranasal - Vyera Pharmaceuticals". AdisInsight. Retrieved 24 September 2017.
  4. Mullin, Emily (February 27, 2015). "Turing Pharma Says Daraprim Availability Will Be Unaffected By Shkreli Arrest". Forbes.com. Retrieved 2 February 2016.
  5. Weintraub, Arlene (February 27, 2015). "Gadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin". Forbes.com. Retrieved 19 December 2015.
  6. "Convicted pharma fraudster Shkreli's companies file for bankruptcy". Wall Street Journal. May 10, 2023. Retrieved May 10, 2023.
  7. "Launch of Turing Pharmaceuticals Announced – New Drug Company to Focus on Treating Unmet Medical Needs Across Broad Therapeutic Areas". Turingpharma.com. February 24, 2015. Archived from the original on 26 September 2015. Retrieved 19 December 2015.
  8. "Turing Pharmaceuticals AG Acquires U.S. Marketing Rights to DARAPRIM® (pyrimethamine)". Turingpharma.com. August 10, 2015. Archived from the original on 4 March 2016. Retrieved 19 December 2015.
  9. Timmermann, Like (September 23, 2015). "A Timeline of the Turing Pharma Controversy". Forbes.com. Retrieved 19 December 2015.
  10. "Martin Shkreli resigns from Turing Pharmaceuticals after fraud charges". Theguardian.com. December 19, 2015. Retrieved 19 December 2015.
  11. Ariana Eunjung Cha (2015-09-22). "CEO who raised price of old pill more than $700 calls journalist a 'moron' for asking why". The Washington Post .
  12. "Turing Pharmaceuticals LLC Announces Improvements in Daraprim Accessibility and Affordability". Turingpharma.com. October 13, 2015. Archived from the original on 22 December 2015. Retrieved 19 December 2015.
  13. "Turing Reduces Cost of Daraprim® (pyrimethamine)". Turingpharma.com. November 24, 2015. Archived from the original on 22 December 2015. Retrieved 19 December 2015.
  14. "Archived copy" (PDF). Archived from the original (PDF) on 2016-03-20. Retrieved 2016-02-04.{{cite web}}: CS1 maint: archived copy as title (link)
  15. "Vyera Pharmaceuticals, LLC". Federal Trade Commission . January 27, 2020.
  16. "'Pharma Bro' firm reaches $40M settlement in gouging case". AP News . December 8, 2021.
  17. Koenig, Bryan (December 7, 2021). "Former Shkreli Co. Inks Deal Worth Up To $40M With FTC, AGs - Law360". Law360 .
  18. "Retrophin Signs U.S. License Agreement for Syntocinon™ Nasal Spray (Oxytocin)". Business Wire. December 12, 2013. Retrieved 19 December 2015.
  19. "Turing Pharmaceuticals AG Announces IND Filing for TUR-004". Turingpharma.com. October 5, 2015. Archived from the original on 22 December 2015. Retrieved 19 December 2015.
  20. "Turing Initiates Dosing in Phase I Clinical Trial of TUR 004 for Epileptic Encephalopathies". Turinpharma.com. November 16, 2015. Archived from the original on 22 December 2015. Retrieved 19 December 2015.